Learn how aggressive neuroendocrine carcinoma disrupts daily life—and why rapid treatment, strong caregiver support, and navigation resources matter. In this episode, ‘Current Treatments and Biomarker ...

Colorectal cancer (CRC) remains one of the most heterogeneous malignancies, with substantial variability in molecular ...

Bladder cancer (BLCA) is the most prevalent malignant tumor of the urinary system. Mitophagy is a selective form of autophagy that occurs within the mitochondria. The goal of this study was to ...

Metastatic breast cancer subtypes and biomarkers are crucial for guiding treatment decisions and managing disease progression. ER-positive, HER2-negative breast cancer treatment often begins with ...

A Northwestern Medicine study has offered new clues as to why immunotherapy works well for some bladder cancer patients but fails for others, according to a study published in the Journal of Clinical ...

Biomarker testing in colorectal cancer (CRC) informs doctors about unique features of cancer that may influence its growth, spread, recurrence, and treatment response. Colorectal cancer (CRC), which ...

Gastric cancer remains one of the leading causes of cancer mortality worldwide, largely as a result of late‐stage diagnosis and heterogeneity in tumour biology. Circulating biomarkers have emerged as ...

Region-specific biomarkers FGFR4, FLT1, and WNT5A are linked to tumor behavior and therapeutic response in CRC. Comprehensive genomic profiling (CGP) aids in precision medicine by identifying genetic ...

Early detection and prevention of cancer can save lives, but current tools often fall short because of suboptimal accuracy and limited accessibility. The Fred Hutch Cancer Center aims to change that ...

Dr. Sita Kugel’s team recently published two papers identifying a key biological signature that not only provides clinics a faster, cheaper way to tell pancreatic cancer subtypes apart, but reveals a ...

A risk model that combines a mammographic artificial intelligence (AI) risk score with polygenic and clinical risk scores ...